Abivax is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory diseases. Its lead program, obefazimod, targets conditions such as ulcerative colitis by modulating immune pathways rather than relying on classic immunosuppressants alone. With little commercial product revenue, value hinges on late-stage clinical progress and potential partnerships for inflammatory bowel disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -52.4 | — |
| Q2 2025 | 0 | — | -48.4 | — |
| Q3 2025 | 0 | — | -153.4 | — |
| Q4 2025 | 0 | — | -82 | — |
| Q1 2026 | 0 | — | -48.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Zions Bancorporation, National Association (ZION), Hut 8 Corp. (HUT), Kratos Defense & Security Solutions, Inc. (KTOS), Protagonist Therapeutics, Inc. (PTGX), Liberty Live Holdings, Inc. (LLYVK), Sirius XM Holdings Inc. (SIRI)